“2023: Discover the Top 5 Pharmaceutical ETFs!

As of this writing in the year 2023, the five biggest Pharmaceutical ETFs are all currently beating the market. These five ETFs are providing big returns to investors, with all five of them having returned more than seventeen percent so far this year. Investing in ETFs, or Exchange Traded Funds, provides investors with an easy way to diversify their holdings and reduce the amount of risk in their personal portfolios. In comparison to mutual funds, ETFs can often be bought and sold much more quickly and without any sales commissions or fees. The first of the five biggest pharmaceutical ETFs of 2023 is ARK Pharmatech (ARKP). This fund tracks the S&P 500 Healthcare Sector Index and provides exposure to some of the largest companies in the pharmaceuticals industry. Companies like Merck & Co, Pfizer, Novartis, Johnson & Johnson, and GlaxoSmithKline make up the top ten holdings in ARK Pharmatech. The fund has returned 19.97% since January of this year. The second biggest pharmaceutical ETF of 2023 is iShares US Pharmaceuticals ETF (IHE). This fund is based on the Dow Jones US Pharmaceuticals Index and focuses on the larger pharmaceuticals companies in the United States. Some of the top holdings include Johnson & Johnson, Pfizer, Merck & Co, Bristol-Myers Squib, and Eli Lilly. The fund has returned 19.26% this year. In the third spot is the SPDR Pharmaceuticals ETF (XPH). This fund tracks the S&P Pharmaceuticals Select Industry Index. It provides exposure to some of the biggest names in the pharmaceuticals industry including Johnson & Johnson, Pfizer, Merck & Co, AbbVie, and Novartis. As of this writing, the fund has returned 19.09% since January of this year. The fourth spot is taken by the Vanguard Pharmaceuticals ETF (PHA). This fund follows the NASDAQ US Select Pharmaceuticals Index. Top holdings include Johnson & Johnson, Pfizer, Merck & Co, AbbVie, and Eli Lilly. Vanguard Pharmaceuticals has returned 18.41% since the start of the year. The fifth biggest pharmaceutical ETF of 2023 is the SPDR S&P Pharmaceuticals ETF (XPHN). This fund tracks the S&P Pharmaceuticals Total Return Index, directing investments into the larger pharmaceuticals companies in the United States. The top companies held in the fund include Johnson & Johnson, Pfizer, Merck & Co, Novartis, and GlaxoSmithKline. Since January of this year, the fund has returned 17.41%. In conclusion, for those investors looking to diversify their portfolios and gain exposure to the pharmaceuticals industry, these five ETFs are worth a look. With all five of them having beaten the market this year, each could prove to be a good investment in the foreseeable future. As always, it is important to keep one’s investments diversified and to consider risk management strategies before making any investments.